This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2016 Dec 10;388(10062):2842-2844.

doi: 10.1016/S0140-6736(16)32107-9. Epub 2016 Nov 16.

Targeting tau protein in Alzheimer's disease

Michael S Rafii¹

Affiliations

Affiliation

¹ Alzheimer's Therapeutic Research Institute, University of Southern California, CA, USA; Department of Neuroscience, University of California, San Diego, CA 92121, USA. Electronic address: mrafii@usc.edu.

PMID: 27863808
DOI: 10.1016/S0140-6736(16)32107-9

Comment

Targeting tau protein in Alzheimer's disease

Michael S Rafii. Lancet. 2016.

. 2016 Dec 10;388(10062):2842-2844.

doi: 10.1016/S0140-6736(16)32107-9. Epub 2016 Nov 16.

Author

Michael S Rafii¹

Affiliation

¹ Alzheimer's Therapeutic Research Institute, University of Southern California, CA, USA; Department of Neuroscience, University of California, San Diego, CA 92121, USA. Electronic address: mrafii@usc.edu.

PMID: 27863808
DOI: 10.1016/S0140-6736(16)32107-9

No abstract available

PubMed Disclaimer

Comment on

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.
Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ, Schelter BO, Davis CS, Staff RT, Bracoud L, Shamsi K, Storey JM, Harrington CR, Wischik CM. Gauthier S, et al. Lancet. 2016 Dec 10;388(10062):2873-2884. doi: 10.1016/S0140-6736(16)31275-2. Epub 2016 Nov 16. Lancet. 2016. PMID: 27863809 Free PMC article. Clinical Trial.

Similar articles

Tau and beyond for Alzheimer's disease.
Gong CX, Alonso Adel C. Gong CX, et al. J Alzheimers Dis. 2013;37(3):465-6. doi: 10.3233/JAD-130490. J Alzheimers Dis. 2013. PMID: 24064504 No abstract available.
STOX1A induces phosphorylation of tau proteins at epitopes hyperphosphorylated in Alzheimer's disease.
van Abel D, Abdulhamid O, Scheper W, van Dijk M, Oudejans CB. van Abel D, et al. Neurosci Lett. 2012 Oct 24;528(2):104-9. doi: 10.1016/j.neulet.2012.09.017. Epub 2012 Sep 17. Neurosci Lett. 2012. PMID: 22995177
[Expression of tau-related protein in spinal cord of patients with Alzheimer's disease].
GUO YJ, WANG LN, ZHU MW, ZHANG HH, HU YZ, HAN ZT, LI JM, WANG DX. GUO YJ, et al. Zhonghua Bing Li Xue Za Zhi. 2011 Mar;40(3):161-4. Zhonghua Bing Li Xue Za Zhi. 2011. PMID: 21575385 Chinese.
Yeast Model of Amyloid-β and Tau Aggregation in Alzheimer's Disease.
Moosavi B, Mousavi B, Macreadie IG. Moosavi B, et al. J Alzheimers Dis. 2015;47(1):9-16. doi: 10.3233/JAD-150173. J Alzheimers Dis. 2015. PMID: 26402750 Review.
[Phosphorylation of tau and Alzheimer's disease].
García T, Jay D. García T, et al. Gac Med Mex. 2004 May-Jun;140(3):329-33. Gac Med Mex. 2004. PMID: 15259345 Review. Spanish.

See all similar articles

Cited by

Amyloidogenesis: What Do We Know So Far?
Alraawi Z, Banerjee N, Mohanty S, Kumar TKS. Alraawi Z, et al. Int J Mol Sci. 2022 Nov 12;23(22):13970. doi: 10.3390/ijms232213970. Int J Mol Sci. 2022. PMID: 36430450 Free PMC article. Review.
Discovery of MAO-B Inhibitor with Machine Learning, Topomer CoMFA, Molecular Docking and Multi-Spectroscopy Approaches.
Zheng L, Qin X, Wang J, Zhang M, An Q, Xu J, Qu X, Cao X, Niu B. Zheng L, et al. Biomolecules. 2022 Oct 13;12(10):1470. doi: 10.3390/biom12101470. Biomolecules. 2022. PMID: 36291679 Free PMC article.
Differential expression of plasma exosomal microRNA in severe acute pancreatitis.
Xu Y, Sun Y, Yin R, Dong T, Song K, Fang Y, Liu G, Shen B, Li H. Xu Y, et al. Front Pharmacol. 2022 Sep 28;13:980930. doi: 10.3389/fphar.2022.980930. eCollection 2022. Front Pharmacol. 2022. PMID: 36249739 Free PMC article.
Neurogranin: A Potential Biomarker of Neurological and Mental Diseases.
Xiang Y, Xin J, Le W, Yang Y. Xiang Y, et al. Front Aging Neurosci. 2020 Oct 6;12:584743. doi: 10.3389/fnagi.2020.584743. eCollection 2020. Front Aging Neurosci. 2020. PMID: 33132903 Free PMC article. Review.
A dual inhibitor of the proteasome catalytic subunits LMP2 and Y attenuates disease progression in mouse models of Alzheimer's disease.
Yeo IJ, Lee MJ, Baek A, Miller Z, Bhattarai D, Baek YM, Jeong HJ, Kim YK, Kim DE, Hong JT, Kim KB. Yeo IJ, et al. Sci Rep. 2019 Dec 5;9(1):18393. doi: 10.1038/s41598-019-54846-z. Sci Rep. 2019. PMID: 31804556 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information